0.00Open0.00Pre Close0 Volume0 Open Interest7.00Strike Price0.00Turnover1002.90%IV38.54%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.1438Delta0.0308Gamma15.19Leverage Ratio-0.5810Theta-0.0001Rho-2.18Eff Leverage0.0017Vega
Inovio Pharmaceuticals Stock Discussion
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet